Profil
Graham Parry worked as Biology Director at Attenuon, LLC and as Principal at Motility, Inc. He also worked as Vice President-Technical Operations at True North Therapeutics, Inc. from 2014 to 2017.
Parry received his undergraduate degree from Brunel University and his doctorate degree from the University of London.
Anciens postes connus de Graham Parry
| Sociétés | Poste | Fin |
|---|---|---|
True North Therapeutics, Inc.
 True North Therapeutics, Inc. BiotechnologyHealth Technology True North Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, and commercialization of first-in-class product candidates for complement-mediated diseases. The company was founded by Nancy E. Stagliano in 2013 and is headquartered in South San Francisco, CA. | Directeur Technique/Scientifique/R&D | 01/01/2017 |
| Motility, Inc. | Corporate Officer/Principal | - |
| Attenuon, LLC | Corporate Officer/Principal | - |
Formation de Graham Parry
| Brunel University | Undergraduate Degree |
| University of London | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
| Attenuon, LLC | |
| Motility, Inc. | |
True North Therapeutics, Inc.
True North Therapeutics, Inc. BiotechnologyHealth Technology True North Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, and commercialization of first-in-class product candidates for complement-mediated diseases. The company was founded by Nancy E. Stagliano in 2013 and is headquartered in South San Francisco, CA. | Health Technology |
